GLP-1 Market
LLY $1169.60 ▼ -1.6% NVO $38.18 ▼ -0.2% PFE $27.82 ▼ -0.6% VKTX $27.73 ▼ -2.8% KLRA $10.00 ▼ -5.0% GPCR $25.67 ▼ -3.8% RHHBY $53.29 ▼ -1.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Garetosmab

Company
Regeneron Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 9, 2026

Trial details
  • Completed NCT NCT02870400

    A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

    Not yet reported Regeneron Pharmaceuticals 41 participants Est. completion 2017-01-12 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02943239

    Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

    Not yet reported Regeneron Pharmaceuticals 82 participants Est. completion 2019-04-30 2 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03188666

    A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

    Not yet reported Regeneron Pharmaceuticals 44 participants Est. completion 2021-09-16 11 sites Stand-alone
    Other conditions: Fibrodysplasia Ossificans Progressiva
    View official trial listing →
  • Withdrawn NCT NCT03710941

    Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

    Not yet reported Regeneron Pharmaceuticals Est. completion 2020-11-05 Stand-alone
    Other conditions: Sporadic Inclusion Body Myositis
    View official trial listing →
  • Withdrawn NCT NCT04577820

    Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

    Not yet reported Regeneron Pharmaceuticals Est. completion 2022-10-08 Stand-alone
    Other conditions: Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO)
    View official trial listing →
  • Active, not recruiting NCT NCT05394116

    A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

    Not yet reported Regeneron Pharmaceuticals 63 participants Est. completion 2029-02-27 22 sites Stand-alone
    Other conditions: Fibrodysplasia Ossificans Progressiva
    View official trial listing →
  • Active, not recruiting NCT NCT06299098

    A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

    Not yet reported Regeneron Pharmaceuticals 1005 participants Est. completion 2026-10-21 60 sites Added to GLP-1
    Other conditions: Obesity
    View official trial listing →
  • Withdrawn NCT NCT06970405

    Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

    Not yet reported Regeneron Pharmaceuticals Est. completion 2026-06-08 Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Temporarily Not Available NCT NCT07301450

    An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

    Regeneron Pharmaceuticals
    Other conditions: Fibrodysplasia Ossificans Progressiva (FOP)
    View official trial listing →
  • Not yet recruiting NCT NCT07559513

    A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)

    Not yet reported Regeneron Pharmaceuticals 18 participants Est. completion 2030-07-08 Stand-alone
    Other conditions: Fibrodysplasia Ossificans Progressiva, FOP
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Garetosmab, Pasatru, REGN2477

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.